


PTO/SB/08A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT 				Complete if Known	
				Application Number	10/676,222
				Filing Date	October 1, 2003
				Confirmation Number	9712
				First Named Inventor	Robert A. Holton
				Group Art Unit	TBA
Examiner Name	TBA				
Sheet	1	of	1	Attorney Docket No.	FSUM 10462.50

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
<i>Av</i>	85	EP	0 882 732	A1	Ensuiiko Sugar Refining Company, Limited	12-09-1998	
OTHER ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ⁶
<i>Av</i>	86	Journal of Chinese Universities, (2000), pp. 401-406, Vol. 21:3					
<i>Av</i>	87	Journal of Tianjin University, (2000), pp. 51-55, Vol. 33:1					Y

Examiner Signature	<i>Amelia Jones</i>	Date Considered	3/3/2006
--------------------	---------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/676,222
		Filing Date	October 1, 2003
		Confirmation Number	9712
		First Named Inventor	Robert A. Holton
		Group Art Unit	1714
		Examiner Name	Not yet assigned
Sheet 1 of 7	Attorney Docket No.	FSUM 10462.50	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
AS	1	5,175,315		Holton	12-29-1992
	2	5,200,534		Rao	04-06-1993
	3	5,227,400		Holton et al.	07-13-1993
	4	5,243,045		Holton et al.	09-07-1993
	5	5,250,683		Holton et al.	10-05-1993
	6	5,254,580		Chen et al.	10-19-1993
	7	5,283,253		Holton et al.	02-01-1994
	8	5,350,866		Holton et al.	09-27-1994
	9	5,367,086		Rao	11-22-1994
	10	5,407,674		Bruno Gabetta et al.	04-18-1995
	11	5,430,160		Holton	07-04-1995
	12	5,475,011		Iwao Ojima et al.	12-12-1995
	13	5,556,878		Kelley et al.	09-17-1996
	14	5,567,614		Patel et al.	10-22-1996
AS	15	5,614,645		Kingston et al.	03-25-1997

Examiner Signature	<i>Amelia J. Davis</i>	Date Considered	3/3/2006
-----------------------	------------------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/676,222
				Filing Date	October 1, 2003
				Confirmation Number	9712
				First Named Inventor	Robert A. Holton
				Group Art Unit	1714
				Examiner Name	Not yet assigned
Sheet	2	of	7	Attorney Docket No.	FSUM 10462.50


16	5,714,513		Holton et al.	02-03-1998
17	5,721,268		Holton et al.	02-24-1998
18	5,739,362		Holton et al.	04-14-1998
19	5,756,776		Bombardelli et al.	05-26-1998
20	5,767,297		Mandai et al.	06-16-1998
21	5,780,653		Tao et al.	07-14-1998
22	5,811,452		Ojima et al.	09-22-1998
23	5,879,929		Patel	03-09-1999
24	5,889,043		Bouchard et al.	03-30-1999
25	5,906,990		Bouchard et al.	05-25-1999
26	5,912,264		Wittman et al.	06-15-1999
27	5,959,125		Bouchard et al.	09-28-1999
28	5,965,739		Kelly et al.	10-12-1999
29	2001/0002404	A1	Webb et al.	05-31-2001

Examiner Signature	<i>[Signature]</i>	Date Considered	3/3/2006
--------------------	--------------------	-----------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 				Complete if Known	
				Application Number	10/676,222
				Filing Date	October 1, 2003
				Confirmation Number	9712
				First Named Inventor	Robert A. Holton
				Group Art Unit	1714
				Examiner Name	Not yet assigned
Sheet	3	of	7	Attorney Docket No.	FSUM 10462.50

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
AO	30	EP	0 534 709	A1	Florida State University	03-31-1993	
	31	EP	0 558 959	B1	Bristol-Myers Squibb Co.	09-08-1993	
	32	EP	0 590 267	A2	Bristol-Myers Squibb Company	04-06-1994	
	33	EP	0 590 267	A3	Bristol-Myers Squibb Company	04-06-1994	
	34	EP	0 600 517	B1	Bristol-Myers Squibb Co.	06-08-1994	
	35	EP	0 604 910	B1	Bristol-Myers Squibb Company	07-06-1994	
	36	EP	0 629 701	A1	Bristol-Myers Squibb Co.	12-21-1994	
	37	EP	0 639 577	A1	Bristol-Myers Squibb Company	02-22-1995	
	38	WO	93/18018	A1	University of Florida	09-16-1993	
	39	WO	93/23389	A1	Rhone-Poulenc Rorer	11-25-1993	
	40	WO	94/07880	A1	Rhone-Poulenc Rorer	04-14-1994	
	41	WO	94/13655	A1	The Upjohn Company	06-22-1994	
	42	WO	94/20484	A1	Rhone-Poulenc Rorer S.A.	09-15-1994	
AO	43	WO	95/04154	A1	Nippon Steel Corporation	02-09-1995	

Examiner Signature		Date Considered	3/3/2006
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/676,222
				Filing Date	October 1, 2003
				Confirmation Number	9712
				First Named Inventor	Robert A. Holton
				Group Art Unit	1714
				Examiner Name	Not yet assigned
Sheet	4	of	7	Attorney Docket No.	FSUM 10462.50


44	WO	96/13495	A1	The Research Foundation of State University of New York	05-09-1996	
45	WO	97/09979	A1	Florida State University	03-20-1997	
46	WO	97/32578	A1	The Research Foundation of State University of New York	09-12-1997	
47	WO	97/42181	A1	Florida State University	11-13-1997	
48	WO	97/44026	A1	Neuromedica, Inc.	11-27-1997	
49	WO	97/44063	A1	Neuromedica, Inc.	11-27-1997	
50	WO	98/02426	A1	Kabushiki Kaisha Yakult Honsha	01-22-1998	
51	WO	99/09021	A1	Florida State University	02-25-1999	
52	WO	99/14209	A1	Kabushiki Kaisha Yakult Honsha	03-25-1999	
53	WO	99/32473	A1	Kabushiki Kaisha Yakult Honsha	07-01-1999	
54	WO	00/53592	A1	Asahi Kasei Kogyo Kabushiki Kaisha, JP	09-14-2000	
55	WO	01/57013	A1	Florida State University Research Foundation, Inc.	08-09-2001	
56	WO	01/57032	A1	Florida State University Research Foundation, Inc.	08-09-2001	
57	WO	01/68089	A1	Indena SPA	09-20-2001	

Examiner Signature	<i>Amelia Jones</i>	Date Considered	3/3/2006
--------------------	---------------------	-----------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 				Application Number	10/676,222
				Filing Date	October 1, 2003
				Confirmation Number	9712
				First Named Inventor	Robert A. Holton
				Group Art Unit	1714
				Examiner Name	Not yet assigned
Sheet	5	of	7	Attorney Docket No.	FSUM 10462.50


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
AO	58	APPENDINO et al. "Synthesis of Paclitaxel (Docetaxel) / 2-Deacetoxytaxinine J Dimers" Tetrahedron, Vol. 55 (1999) pp. 6567-6576.	
	59	CRAVALLEE et al. "Methyleniminium Salts as Acylating Agent - One Step Synthesis of Baccatin III from 10-Deacetylbaaccatin III with High Selectivity" Tetrahedron Letters, Vol. 39 (1998) pp. 4263-4266.	
	60	DUBOIS et al. "Fluorescent and Biotinylated Analogues of Docetaxel: Synthesis and Biological Evaluation" Bioorganic & Medicinal Chemistry, Vol. 3, No. 10 (1995) pp. 1357-1368.	
	61	GUENARD et al. "Effects of the Hydrophobicity of Taxoids on Their Interaction with Tubulin" Bioorganic & Medicinal Chemistry, Vol. 8 (2000) pp. 145-156.	
	62	GUERITTE-VOEGELEIN et al. "Relationships between the Structure of Taxol Analogues and Their Antimitotic Activity" Journal of Medicinal Chemistry, Vol. 34, No. 3 (1991) pp. 992-998.	
	63	ISHIHARA et al. "Scandium Trifluoromethanesulfonate as an Extremely Active Acylation Catalyst" J. Am. Chem. Soc., Vol. 117, No. 15 (1995) pp. 4413-4414.	
	64	KANT et al. "A Chemoselective Approach to Functionalize the C-10 Position of 10-Deacetylbaaccatin III. Synthesis and Biological Properties of Novel C-10 Taxol Analogues" Tetrahedron Letters, Vol. 35, No. 30 (1994) pp. 5543-5546.	
	65	KIRIKAE et al. "Structural Significance of the Acyl Group at the C-10 Position and the A Ring of the Taxane Core of Paclitaxel for Inducing Nitric Oxide and Tumor Necrosis Factor Production by Murine Macrophages" FEBS Letters, Vol. 478 (2000) pp. 221-226.	
AO	66	KIRIKAE et al. "Structural Requirements of Taxoids for Nitric Oxide and Tumor Necrosis Factor Production by Murine Macrophages" Biochemical and Biophysical Research Communications, Vol. 227 (1996) pp. 227-235 (Article No. 1494).	

Examiner Signature		Date Considered	3/3/2006
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) 				Application Number	10/676,222
				Filing Date	October 1, 2003
				Confirmation Number	9712
				First Named Inventor	Robert A. Holton
				Group Art Unit	1714
				Examiner Name	Not yet assigned
Sheet	6	of	7	Attorney Docket No.	FSUM 10462.50


67	KOBAYASHI et al. "Modulation of Multidrug Resistance by Taxuspine C and Other Taxoids from Japanese Yew" Bioorganic & Medicinal Chemistry Letters, Vol. 8 (1998) pp. 1555-1558.
68	LIN et al. "Synthesis of Highly Potent Second-Generation Taxoids Through Effective Kinetic Resolution Coupling of Racemic β -Lactams with Baccatins" CHIRALITY, Vol. 12, No. 5/6 (2000) pp. 431-441.
69	OJIMA et al. "Synthesis and Structure - Activity Relationships of the Second-Generation Antitumor Taxoids: Exceptional Activity Against Drug-Resistant Cancer Cells" J. Med. Chem., Vol. 39, No. 20 (1996) pp. 3889-3896.
70	OJIMA et al. "Synthesis and Biological Activity of Novel 3'-Trifluoromethyl Taxoids" Bioorganic & Medicinal Chemistry, Vol. 7, No. 2 (1997) pp. 133-138.
71	OJIMA et al. "Synthesis of Novel 3'-Trifluoromethyl Taxoids Through Effective Kinetic Resolution of Racemic 4-CF ₃ - β -Lactams With Baccatins" Chirality, Vol. 9 (1997) pp. 487-494.
72	OJIMA et al. "Efficient Asymmetric Synthesis of β -Lactams Bearing A Cyclopropane or an Epoxide Moiety and Their Application to the Synthesis of Novel Isoserines and Taxoids" Journal of Organic Chemistry, Vol. 63, No. 2 (1998) pp. 224-225.
73	OJIMA et al. "New Photoaffinity Analogs of Paclitaxel" Bioorganic & Medicinal Chemistry Letters, Vol. 9 (1999) pp. 1189-1194.
74	OJIMA et al. "Enantiopure Fluorine-Containing Taxoids: Potent Anticancer Agents and Versatile Probes for Biomedical Problems" Journal of Fluorine Chemistry, Vol. 97 (1999) pp. 3-10.
75	OJIMA et al. "Synthesis and Structure-Activity Relationships of New Second-Generation Taxoids, Bioorganic & Medicinal Chemistry Letters, Vol. 9 (1999) pp. 3423-3428.
76	OJIMA et al. "Synthesis and Biological Activity of C-3'-Difluoromethyl-Taxoids" Bioorganic & Medicinal Chemistry, Vol. 8, No. 7 (2000) pp. 1619-1628.
77	RAO et al. "Synthesis and Evaluation of Some 10-Mono- and 2',10-Diesters of 10-Deacetylpaclitaxel" J. Med. Chem., Vol. 38, No. 17 (1995) pp. 3411-3414.
78	SENGUPTA et al. "Probing the Environment of Tubulin-Bound Paclitaxel Using Fluorescent Paclitaxel Analogues" Biochemistry, Vol. 36, No. 17 (1997) pp. 5179-5184.

Examiner Signature		Date Considered	3/3/2006
--------------------	---	-----------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A			Compleat if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 			Application Number	10/676,222	
			Filing Date	October 1, 2003	
			Confirmation Number	9712	
			First Named Inventor	Robert A. Holton	
			Group Art Unit	1714	
			Examiner Name	Not yet assigned	
Sheet	7	of	7	Attorney Docket No.	FSUM 10462.50

79	SENILH et al. "Mise en evidence de nouveaux analogues du taxol extraits de taxus baccata" Journal of Natural Products, Vol. 47, No. 1 (Jan/Feb 1984) pp. 131-137.	
80	SHI et al. "Studies on the Quantitative Structure-activity Relationships of Paclitaxel Analogues" Gaodeng Xuexiao Huaxue Xuebao, Vol. 21, No. 3 (2000) pp. 401-406. (English Abstract attached)	
81	STRAUBINGER et al. "Pharmacology and Antitumor Effect of Novel Paclitaxel Formulations" Chapter 8, Edited by G. Georg et al., Taxane Anticancer Agents, Basic Science and Current Status, ACS Symposium Series 583, 207th National Meeting of the American Chemical Society, San Diego, CA (1994) pp. 111-123.	
82	International Search Report for analogous PCT Application No. PCT/US01/03623 dated June 8, 2001.	
83	European Search Report for analogous EP Application No. 01118728 dated November 14, 2001.	
84	Georgian Search Report from AP 2001 004523 dtd 02/26/2003	

Examiner Signature		Date Considered	3/3/2006
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.